🟢 DexCom is trading 10% up today after beating Q2 estimates and raising full-year guidance

DexCom is trading 10% up at $82.00 after beating second-quarter 2026 estimates and raising its full-year revenue and margin guidance.

• The company reported 13% year-over-year revenue growth alongside a significant 590-basis-point operating margin expansion.
• Management issued a bullish outlook highlighted by a strategic expansion into the non-insulin Type 2 diabetes market, signaling stronger long-term profitability.